Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
View original at finance.yahoo.comChronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment
80% confidenceDespite improved outcomes, current therapies only delay progression and cannot halt or reverse CKD, highlighting a major and persistent unmet need
80% confidenceThe United States accounts for the largest market size of chronic kidney disease, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan
80% confidenceCKD cases are projected to increase further over the forecast period (2025-2034) due to the aging population
80% confidenceThe CKD therapy market includes RAAS inhibitors as the standard of care and the rapidly growing use of SGLT-2 inhibitors such as FARXIGA and JARDIANCE as emerging front-line options
80% confidenceKIM-1 and NGAL enable earlier, more precise detection of CKD than traditional methods, improving the potential for timely intervention and better patient outcomes
80% confidenceThe distribution of End-Stage Kidney Disease (ESKD) cases across the 7MM indicates that the number of patients on dialysis exceeds that of those receiving kidney transplants
80% confidenceIn 2024, there were approximately 82 million prevalent cases of CKD in the 7MM
80% confidenceThe chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations
80% confidenceThe CKD market size in the 7MM was approximately USD 4.8 billion in 2024 and is expected to increase further by 2034
80% confidenceZibotentan/dapagliflozin combination has the potential to reduce mortality and delay the onset of end-stage kidney disease (ESKD)
80% confidenceNo current medications can reverse CKD
80% confidenceIn 2024, there were nearly 14.5 million total diagnosed cases of CKD in the 7MM
80% confidence